World's Best Scientists 2026 revealed!
Award Badge
Medicine
Netherlands
2023

D-Index & Metrics

Medicine

D-Index
137
Citations
103403
World Ranking
1859
National Ranking
70

Jaap Verweij publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jaap Verweij sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 832 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jaap Verweij D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jaap Verweij sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 137 D-Index — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Netherlands Leader Award
  • 2011 - Royal Netherlands Academy of Arts and Sciences

Overview

Jaap Verweij is affiliated with Erasmus University Rotterdam in the Netherlands, where the primary focus of their research is in the field of Medicine, with particular expertise in Oncology, Cancer Research, and Epidemiology. Their work spans a range of subfields such as Economics and Econometrics, Pulmonary and Respiratory Medicine, and several intersecting areas of cancer research and health systems analysis.

The scientist's research addresses topics including Cancer Genomics and Diagnostics, Cervical Cancer and HPV Research, Health Systems and Economic Evaluations, Genetic factors in colorectal cancer, Colorectal and Anal Carcinomas, Economic and Financial Impacts of Cancer, and Pharmaceutical Economics and Policy. This breadth of topics indicates engagement with both biomedical and systemic approaches to cancer and healthcare.

Key recent publications by Verweij demonstrate a focus on cancer biology and health outcomes:

  • "Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site," 2020, British Journal of Cancer
  • "Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe," 2020, Cancers
  • "Empowering effective biomarker-driven precision oncology: A call to action," 2024, European Journal of Cancer
  • "Ektacytometry Analysis of Post-splenectomy Red Blood Cell Properties Identifies Cell Membrane Stability Test as a Novel Biomarker of Membrane Health in Hereditary Spherocytosis," 2021, Frontiers in Physiology
  • "StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs)," 2024, Journal of Clinical Oncology

Frequent collaborators in Verweij's work include B. Dekeyser, Barend J. Sikkema, Peter de Bruijn, F. Wastelin, and François Zammit, each contributing to multiple publications. This suggests a consistent research network supporting studies across oncology, pharmacology, and related biomedical fields.

Verweij has published extensively in recognized venues such as the British Journal of Cancer, European Journal of Cancer, Cancers, Frontiers in Physiology, and the Journal of Clinical Oncology. These publication venues reflect the multidisciplinary nature of their research spanning clinical oncology, physiology, and cancer policy evaluation.

In recognition of contributions to science, Jaap Verweij was awarded membership by the Royal Netherlands Academy of Arts and Sciences in 2011. This accolade indicates peer recognition within the Netherlands scientific community.

Best Publications

  • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

    Elizabeth Eisenhauer;Patrick Therasse;Jan Bogaerts;L.H. Schwartz

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

    Hans Gelderblom;Jaap Verweij;Kees Nooter;Alex Sparreboom

  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*

    Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne

  • Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

    Allan T van Oosterom;Ian Judson;Jaap Verweij;Sigrid Stroobants

  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

    Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer

  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Ian Judson;Jaap Verweij;Hans Gelderblom;Jörg T Hartmann;Jörg T Hartmann

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

    Stefan Sleijfer;Isabelle Ray-Coquard;Zsuzsa Papai;Axel Le Cesne

  • Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

    Albert J ten Tije;Jaap Verweij;Walter J Loos;Alex Sparreboom;Alex Sparreboom

  • Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

    Johanna C. Bendell;Jordi Rodon;Howard A. Burris;Maja de Jonge

  • Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Isabelle Ray-Coquard;Claire Cropet;Martine Van Glabbeke;Catherine Sebban

  • Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

    M. Van Glabbeke;A.T. van Oosterom;J.W. Oosterhuis;H. Mouridsen

  • Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

    Rolf D Issels;Lars H Lindner;Jaap Verweij;Peter Wust

  • Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

    A Santoro;T Tursz;H Mouridsen;Jaap Verweij

  • Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

    Andrea Ardizzoni;Heine Hansen;Per Dombernowsky;Teresa Gamucci

  • Soft Tissue Sarcomas of Adults State of the Translational Science

    Ernest C. Borden;Laurence H. Baker;Robert S. Bell;Vivien Bramwell

  • Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    J Verweij;A van Oosterom;J.-Y Blay;I Judson

  • Effects of St. John's Wort on Irinotecan Metabolism

    Ron H. J. Mathijssen;Jaap Verweij;Peter de Bruijn;Walter J. Loos

  • Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

    G J Creemers;G Bolis;M Gore;G Scarfone

Frequent Co-Authors

Alex Sparreboom
Alex Sparreboom The Ohio State University
Ron H.J. Mathijssen
Ron H.J. Mathijssen Erasmus University Rotterdam
Stefan Sleijfer
Stefan Sleijfer Erasmus University Rotterdam
Ian Judson
Ian Judson Institute of Cancer Research
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Sharyn D. Baker
Sharyn D. Baker The Ohio State University
Paolo G. Casali
Paolo G. Casali University of Milan
Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online education options can open many doors for aspiring healthcare professionals. For registered nurses looking to advance their credentials without breaking the bank, the cheapest rn to bsn online programs are worth considering. These affordable BSN programs provide flexibility and allow working nurses to continue their education on their own schedule.

Those without a nursing background who are aiming for advanced roles may benefit from direct entry msn programs for non nurses online. These programs are designed for individuals with a bachelor's degree in another field, helping them make a swift transition into nursing.

If you’re just starting your journey and seeking accessible entry points, learning about the easiest rn program can guide you towards schools with higher acceptance rates and less competitive admissions.

Beyond nursing, the healthcare field also needs skilled professionals in administration. Accredited medical billing and coding online schools with financial aid can help students join this in-demand sector, all from the convenience of home.

Best Scientists Citing Jaap Verweij

Trending Scientists

Recently Published Articles